價(jià)格 | 詢價(jià) |
包裝 | As your requirement |
最小起訂量 | As your requirement |
發(fā)貨地 | 上海 |
更新日期 | 2017-08-12 |
中文名稱:右旋糖酐5/10/20/40/70 | 英文名稱:Dextran 5/10/20/40/70 |
CAS:9004-54-0 | 有效期: 一年 |
品牌: YC | 產(chǎn)地: China |
Dextran is a complex branched glucan (polysaccharide made of many glucose molecules) composed of chains of varying lengths (from 3 to 2000 kilodaltons).
The straight chain consists of α-1,6 glycosidic linkages between glucose molecules, while branches begin from α-1,3 linkages.
Dextran was first discovered by Louis Pasteur as a microbial product in wine,but mass production was only possible after the development by Allene Jeanes of a process using bacteria.Dextran is now synthesized from sucrose by certain lactic acid bacteria, the best-known beingLeuconostoc mesenteroides and Streptococcus mutans. Dental plaque is rich in dextrans.
Medicinally it is used as an antithrombotic (antiplatelet), to reduce blood viscosity, and as a volume expander in hypovolaemia.Dextran 70 is on the WHO Model List of Essential Medicines, the most important medications needed in a health system.
These agents are used commonly by microsurgeons to decrease vascular thrombosis. The antithrombotic effect of dextran is mediated through its binding of erythrocytes, platelets, and vascular endothelium, increasing theirelectronegativity and thus reducing erythrocyte aggregation and platelet adhesiveness. Dextrans also reduce factor VIII-Ag Von Willebrand factor, thereby decreasing platelet function. Clots formed after administration of dextrans are more easily lysed due to an altered thrombus structure (more evenly distributed platelets with coarser fibrin. By inhibiting α-2 antiplasmin, dextran serves as a plasminogen activator, so possesses thrombolytic features.
Outside from these features, larger dextrans, which do not pass out of the vessels, are potent osmotic agents, thus have been used urgently to treat hypovolemia. The hemodilution caused by volume expansion with dextran use improves blood flow, thus further improving patency of microanastomoses and reducing thrombosis. Still, no difference has been detected in antithrombotic effectiveness in comparison of intra-arterial and intravenous administration of dextran.
Dextrans are available in multiple molecular weights ranging from 3,000 Da to 2,000,000 Da. The larger dextrans (>60,000 Da) are excreted poorly from the kidney, so remain in the blood for as long as weeks until they are metabolized. Consequently, they have prolonged antithrombotic and colloidal effects. In this family, dextran-40 (MW: 40,000 Da), has been the most popular member for anticoagulationtherapy. Close to 70% of dextran-40 is excreted in urine within the first 24 hours after intravenous infusion, while the remaining 30% are retained for several more days.
成立日期 | 注冊資本 | ||
員工人數(shù) | 年?duì)I業(yè)額 | ||
主營行業(yè) | 醫(yī)藥中間體,原料藥,其他西藥原料 | 經(jīng)營模式 | 工廠 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥400 |
VIP6年
|
湖北鴻福達(dá)生物科技有限公司
|
2025-03-09 | |
詢價(jià) |
VIP6年
|
湖北阡陌生物科技有限公司
|
2025-03-09 | |
詢價(jià) |
VIP4年
|
河南沃咖斯生物科技有限公司
|
2025-03-09 | |
¥390 |
VIP3年
|
山東亞圖生物科技有限公司
|
2025-03-09 | |
¥750 |
VIP7年
|
山東豐泰生物科技有限公司
|
2025-03-09 | |
¥1500 |
VIP4年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-03-09 | |
¥260 |
VIP6年
|
河北創(chuàng)之源生物科技有限公司
|
2025-03-09 | |
¥80 |
VIP1年
|
武漢普世達(dá)生物科技有限公司
|
2025-03-09 | |
¥260 |
VIP1年
|
西安拉維亞生物科技有限公司
|
2025-03-09 | |
¥280 |
VIP3年
|
山東愛采生物科技有限公司
|
2025-03-09 |